Methylergobrevin

• Oxytocics

• Basofortina
• Metenarin
• Methergen
• Methergin
• Methergine
• Methylergobasin
• Methylergobasine
• Methylergobrevin
• Methylergometrin
• Methylergometrine
• Methylergonovin
• Norforms
• Partergin
• Ryegonovin
• Spametrin-M

• No information avaliable

C₂₀H₂₅N₃O₂

http://www.rxlist.com/cgi/generic2/methylerg.htm

Methylergobrevin MSDS

A. Stoll et al., eidem, Helv. Chim. Acta. 26, 944 (1943)

339.432 g/mol

172 ^oC

25 mg/mL

Solid

1.01

Injection (intramuscular or intravenous); Tablet

For the prevention and control of excessive bleeding following vaginal childbirth

Methylergonovine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.

Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.

Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.

Humans and other mammals